文献速递免疫规划

婴儿中研究性肺炎球菌不可分型流感嗜血杆菌蛋白D结合疫苗(PHiD-CV)4剂瓶装与已上市1剂瓶装比较的免疫学非劣效性与安全性:一项III期随机研究

Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
PubMed 文献 · Vaccine · 2017-12-23

在孟加拉国6–10周龄婴儿中开展的III期单中心观察者盲法随机研究显示,研究性含防腐剂PHiD-CV 4剂瓶装与已上市无防腐剂1剂瓶装在基础免疫和加强免疫后,各疫苗型别及19A型抗体几何平均浓度达到非劣效,免疫应答与反应原性范围相似,4剂瓶装有助改善资源有限国家的可及性与覆盖率。

要点

  • 6–10周龄婴儿随机1:1接受4剂瓶装(含防腐剂)或1剂瓶装(无防腐剂)PHiD-CV,基础免疫6、10、18周龄,9月龄加强。
  • 各疫苗型别及19A型抗体GMC非劣效成立,判定标准为1剂瓶装/4剂瓶装抗体GMC比值双侧95%CI上限<2倍。
  • 基础免疫后1个月多数型别每组≥97.9%婴儿抗体浓度≥0.2μg/mL,19A型≥80.1%达到该阈值。

核心结论

  • 研究性含防腐剂PHiD-CV 4剂瓶装对已上市无防腐剂1剂瓶装达到免疫学非劣效,基础与加强免疫后免疫应答及反应原性范围相似。

研究设计与样本

  • III期、单中心、观察者盲法随机研究,在孟加拉国纳入6–10周龄婴儿,按1:1随机接受4剂瓶装(含防腐剂)或1剂瓶装(无防腐剂)PHiD-CV。
  • 基础免疫于6、10、18周龄接种,9月龄加强;DTPw-HBV/Hib按研究方案(联合)接种,脊灰、麻疹和风疹疫苗按国家免疫规划接种。
  • 基础免疫阶段320名婴儿接种(每组160名),其中297名接受了加强免疫。

主要发现

  • 各疫苗型别及19A型均达到非劣效(1剂瓶装/4剂瓶装抗体GMC比值双侧95%CI上限<2倍)。
  • 基础免疫后1个月,多数疫苗型别每组≥97.9%婴儿抗体浓度≥0.2μg/mL,19A型≥80.1%达到该阈值。
  • 基础与加强免疫后两组各疫苗型别及19A型的肺炎球菌抗体应答与调理吞噬活性范围相似,抗蛋白D应答亦相似。
  • 两组均观察到加强免疫应答,报告的不良事件在两种瓶装间范围相似。

关键数值与推荐

  • 非劣效判定标准:1剂瓶装/4剂瓶装抗体GMC比值双侧95%CI上限<2倍。
  • 基础免疫后1个月,多数疫苗型别每组≥97.9%婴儿抗体浓度≥0.2μg/mL;19A型≥80.1%达到该阈值。

临床怎么用

  • 作者认为PHiD-CV 4剂瓶装有助于改善资源有限国家的可及性与覆盖率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To support vaccination programs in developing countries, a 4-dose vial presentation of pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was developed. This study assessed immunologic non-inferiority and safety of the investigational PHiD-CV 4-dose versus licensed 1-dose vial presentation in infants. METHODS: In this phase III, mono-center, observer-blind study in Bangladesh, 6-10-week-old infants were randomized 1:1 to receive PHiD-CV primary vaccination (at ages 6, 10, 18 weeks) and a booster dose (at age 9 months) with a 4-dose vial (with preservative, 4DV group) or 1-dose vial (preservative-free, 1DV group). DTPw-HBV/Hib was (co)-administered per study protocol and polio, measles and rubella vaccines as part of the national immunization program. Non-inferiority of PHiD-CV 4-dose versus 1-dose vial for each vaccine pneumococcal serotype (VT) and vaccine-related serotype 19A in terms of antibody geometric mean concentration (GMC) was assessed (criterion: upper limit of 2-sided 95% confidence interval of antibody GMC ratios [1DV/4DV] <2-fold). Immune responses were measured. Solicited, unsolicited and serious adverse events (AEs) were evaluated. RESULTS: Of 320 infants (160 per group) vaccinated during the primary vaccination phase, 297 received a booster. Non-inferiority was demonstrated for each VT and 19A. One month post-primary vaccination, for most VT, ≥97.9% of infants in each group had antibody concentrations ≥0.2 μg/mL; for 19A ≥ 80.1% reached this threshold. Pneumococcal antibody responses and opsonophagocytic activity for each VT and 19A were within similar ranges between groups after primary and booster vaccination, as were anti-protein D responses. Booster immune responses were observed in both groups. Reported AEs were within similar ranges for both presentations. CONCLUSION: Immunologic non-inferiority of PHiD-CV 4-dose vial (with preservative) versus PHiD-CV 1-dose vial (preservative-free) was demonstrated. Immune responses and reactogenicity following primary/booster vaccination were within similar ranges for both presentations. PHiD-CV 4-dose vial would help improve access and coverage in resource-limited countries. Clinical Trial Registry: NCT02447432.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zaman K, Zaman SF, Zaman F, et al. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study. Vaccine. 2017. PMID: 29277353. doi:10.1016/j.vaccine.2017.12.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。